1Department of Biology Education, Faculty of Teacher Training and Education, Mulawarman University, Samarinda, Indonesia
10Department of Chemistry, Faculty of Mathematics and Natural Sciences, Universitas Negeri Padang, Padang, Indonesia
11Center for Advanced Material Processing, Artificial Intelligence, and Biophysic Informatics (CAMP-BIOTICS), Universitas Negeri Padang, Padang, Indonesia
2Department of Biology, Faculty of Science and Technology, Universitas Airlangga, Surabaya, Indonesia
3Division of Molecular Biology and Genetics, Generasi Biologi Indonesia Foundation, Gresik, Indonesia
4Postgraduate School, Universitas Airlangga, Surabaya, Indonesia
5Uttaranchal Institute of Pharmaceutical Sciences, Uttaranchal University, Dehradun, India
6Medical Faculty, Kabardino-Balkarian State University, Nalchik, Russian Federation
7Department of Scientific Research, V. M. Gorbatov Federal Research Center for Food Systems, Moscow, Russian Federation
8Faculty of Biotechnology and Food Engineering, Ural State Agrarian University, Yekaterinburg, Russian Federation
9Department of Chemistry, Mississippi State University, Mississippi, United States
*Corresponding Author E-mail: rahadianzmsiphd@fmipa.unp.ac.id
Online Published on 07 February, 2024.
SARS-CoV-2 has caused a prolonged COVID-19 pandemic since the end of December 2019 and is still ongoing now. Bioactive compounds can be used as drugs to treat infectious diseases. This study aims to determine C. alata as a drug candidate for COVID-19 through its inhibitory activity to Mpro SARS-CoV-2 in silico. Cassia alata bioactive compounds have the potential to be used as a candidate for anti-SARS-CoV-2 supported by the result of drug-likeness, ADMET, pharmacokinetics, binding affinity, and antiviral activity prediction. Further research needs to be carried out to make C. alata a drug for COVID-19.
SARS-CoV-2, Mpro, Cassia alata, Bioactive compounds
